Raises Fiscal 2025 Outlook Today, Jabil Inc. (NYSE:JBL), reported preliminary, unaudited financial results for its second quarter of fiscal year 2025. Second Quarter of Fiscal Year 2025 Highlights: Net revenue: $6.7 billion U.S. GAAP operating income: $245 million U.S. GAAP diluted earnings per share: $1.06 Core operating income (Non-GAAP): $334 million Core diluted earnings per share (Non-GAAP): $1.94 "I am very pleased with our strong year-to-date results, which underscore the resilience and strength of our diversified portfolio. In Q2, we exceeded our expectations due to continued strength in our capital equipment, cloud and data center infrastructure, and digital commerce

Jabil Inc. (NYSE:JBL) today announced it will release its second quarter of fiscal year 2025 financials on Thursday, March 20, 2025, before the market opens. The company will host a conference call and webcast to review the results. What: Jabil's Second Quarter of Fiscal Year 2025 Conference Call and Webcast When: Thursday, March 20, 2025 – 8:30 a.m. ET Dial-in: U.S. (877) 407-6184 or International (201) 389-0877 To access the live audio webcast and the accompanying slide presentation, visit the Investor Relations section of Jabil's website, located at https://investors.jabil.com. An archived replay of the webcast will be available after completion of the call. About Jabil: At Jabil

A consortium of investors led by Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience Inc. today announced they have exited their equity stake in Pharmaceutics International, Inc. ("Pii"), a contract development and manufacturing organization, and have closed on an undisclosed all-cash transaction to sell the company to Jabil Inc. (NYSE:JBL), a global leader in engineering, manufacturing, and supply chain solutions. Pii is a contract development and manufacturing business, based in Hunt Valley, Maryland, that specializes in the production of aseptic and sterile injectable pharmaceutical products. The company has been offering development and manufactu

Argus downgraded Jabil from Buy to Hold

Barclays reiterated coverage of Jabil with a rating of Overweight and set a new price target of $151.00 from $153.00 previously

Barclays initiated coverage of Jabil with a rating of Overweight and set a new price target of $134.00

4 - JABIL INC (0000898293) (Issuer)

4 - JABIL INC (0000898293) (Issuer)

4 - JABIL INC (0000898293) (Issuer)

8-K - JABIL INC (0000898293) (Filer)

8-K - JABIL INC (0000898293) (Filer)

8-K - JABIL INC (0000898293) (Filer)

Fabrinet (NYSE:FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, today announced that Forbes Alexander has been appointed to the Company's Board of Directors, expanding the Board to eight members. Mr. Alexander will also serve as a member of the Board's Audit Committee. Mr. Alexander is an accomplished leader who brings extensive executive experience and financial knowledge to the Board. Mr. Alexander has served as a founding partner of Steadfast Partners LLP, an industrial technology advisory group, since January 2020. Mr. Alexander served as Execut

When show attendees visit Booth 4375 at NRF'24 and take a photo with Marty, 10 meals will be donated to the Stop & Shop School Food Pantry Program Badger Technologies, a product division of Jabil and pioneer in retail robotics, is joining forces with grocery retail chain Stop & Shop to increase support for Stop & Shop's "Feed it Forward" charitable giving initiatives while reinforcing the positive impact Marty the Robot has made on customers and communities. Stop & Shop is an Ahold Delhaize USA company with nearly 400 stores across the Northeast. Marty's presence in a large majority of Stop & Shop stores strengthens operational efficiencies and helps Stop & Shop serve those in need. This

NEW YORK, Dec. 1, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

Raises Fiscal 2025 Outlook Today, Jabil Inc. (NYSE:JBL), reported preliminary, unaudited financial results for its second quarter of fiscal year 2025. Second Quarter of Fiscal Year 2025 Highlights: Net revenue: $6.7 billion U.S. GAAP operating income: $245 million U.S. GAAP diluted earnings per share: $1.06 Core operating income (Non-GAAP): $334 million Core diluted earnings per share (Non-GAAP): $1.94 "I am very pleased with our strong year-to-date results, which underscore the resilience and strength of our diversified portfolio. In Q2, we exceeded our expectations due to continued strength in our capital equipment, cloud and data center infrastructure, and digital commerce

Jabil Inc. (NYSE:JBL) today announced it will release its second quarter of fiscal year 2025 financials on Thursday, March 20, 2025, before the market opens. The company will host a conference call and webcast to review the results. What: Jabil's Second Quarter of Fiscal Year 2025 Conference Call and Webcast When: Thursday, March 20, 2025 – 8:30 a.m. ET Dial-in: U.S. (877) 407-6184 or International (201) 389-0877 To access the live audio webcast and the accompanying slide presentation, visit the Investor Relations section of Jabil's website, located at https://investors.jabil.com. An archived replay of the webcast will be available after completion of the call. About Jabil: At Jabil

The acquisition of Pii, a science-driven contract development and manufacturing organization (CDMO), complements Jabil's existing pharmaceutical solutions, enabling comprehensive support for customers in drug development, clinical trials, and product commercialization at scale. Jabil Inc. (NYSE:JBL), a global leader in engineering, manufacturing, and supply chain solutions, today announced the successful acquisition of Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO) specializing in early stage, clinical, and commercial volume aseptic filling, lyophilization, and oral solid dose manufacturing, completed February 3, 2025. This press rel

SC 13G/A - JABIL INC (0000898293) (Subject)

SC 13G/A - JABIL INC (0000898293) (Subject)

SC 13G - JABIL INC (0000898293) (Subject)